Key result
In patients with severe septic cardiomyopathy, levosimendan was associated with significant improvements in LVEF and lactate clearance, though ICU survival did not reach statistical significance compared to other treatments.
Why the study?
The optimal treatment of septic cardiomyopathy remains questionable.
Does levosimendan improve left ventricular ejection fraction and survival in mechanically ventilated patients with severe septic cardiomyopathy?
Observational (n=23)
No
Does levosimendan improve left ventricular ejection fraction and survival in mechanically ventilated patients with severe septic cardiomyopathy?
Levosimendan may effectively reverse circulatory failure and improve myocardial function in severe septic cardiomyopathy, though adequately powered randomized trials are needed to confirm survival benefits.
Answers are grounded in this paper and cite their sources.
May improve hemodynamics in septic cardiomyopathy; hypothesis-generating for survival benefit and requires randomized confirmation.
(1) Background: The optimal treatment of septic cardiomyopathy (SCM) remains questionable. The aim of the study was to compare the treatment of SCM based on levosimendan versus the best available therapy. (2) Methods: We conducted an observational study including patients with severe septic cardiomyopathy and circulatory failure. (3) Results: Fourteen patients (61%) received levosimendan, and nine received other treatments. The patients in the levosimendan group were more severely ill [APACHE II: 23.5 (14, 37) vs. 14 (13, 28), respectively, p = 0.012], and there was a trend for more decompensated LV function depicted by the LVEF [15% (10, 20) vs. 25% (5, 30), respectively, p = 0.061]. However, they presented a significantly higher increase in LVEF after seven days [15% (10, 20) to 50% (30, 68) (p < 0.0001) vs. 25% (5, 30) to 25% (15, 50) (p = 0.309), and a significantly higher decrease in lactate levels during the first 24 h [4.5 (2.5, 14.4) to 2.85 (1.2, 15), p = 0.036 vs. 2.9 (2, 18.9) to 2.8 (1, 15), p = 0.536]. Seven-day survival (64.3% vs. 33.3%, p = 0.424) and ICU survival (50% vs. 22.2%, p = 0.172) were higher in the first group, although differences did not reach statistical significance. The degree of left ventricular impairment and the magnitude of EF improvement by the seventh-day post-SCM onset were associated with mortality in regression analysis. (4) Conclusions: Our study presents main hemodynamic data supporting the possible efficacy of levosimendan treatment in patients with severe SCM.
No takes yet. Share an insight, caveat, or question.
Tsolaki et al. (2023) conducted an observational in Severe Septic Cardiomyopathy (n=23). Levosimendan vs. Other treatments (dobutamine or noradrenaline only) was evaluated on ICU survival (p=0.202). In patients with severe septic cardiomyopathy, levosimendan was associated with significant improvements in LVEF and lactate clearance, though ICU survival did not reach statistical significance compared to other treatments.
Synapse has enriched 10 related papers. Consider them for comparative context: